Protalix BioTherapeutics (PLX) Competitors $1.54 +0.05 (+3.00%) Closing price 07/3/2025 03:54 PM EasternExtended Trading$1.54 0.00 (0.00%) As of 07/3/2025 04:32 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock PLX vs. ORGO, PRTC, KMDA, ORKA, ATAI, RAPP, RGNX, ERAS, ABVX, and FULCShould you be buying Protalix BioTherapeutics stock or one of its competitors? The main competitors of Protalix BioTherapeutics include Organogenesis (ORGO), PureTech Health (PRTC), Kamada (KMDA), Oruka Therapeutics (ORKA), atai Life Sciences (ATAI), Rapport Therapeutics (RAPP), REGENXBIO (RGNX), Erasca (ERAS), Abivax (ABVX), and Fulcrum Therapeutics (FULC). These companies are all part of the "pharmaceutical products" industry. Protalix BioTherapeutics vs. Its Competitors Organogenesis PureTech Health Kamada Oruka Therapeutics atai Life Sciences Rapport Therapeutics REGENXBIO Erasca Abivax Fulcrum Therapeutics Organogenesis (NASDAQ:ORGO) and Protalix BioTherapeutics (NYSE:PLX) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their media sentiment, risk, institutional ownership, earnings, profitability, dividends, valuation and analyst recommendations. Which has preferable valuation & earnings, ORGO or PLX? Protalix BioTherapeutics has lower revenue, but higher earnings than Organogenesis. Organogenesis is trading at a lower price-to-earnings ratio than Protalix BioTherapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioOrganogenesis$482.04M1.14$860K-$0.17-25.59Protalix BioTherapeutics$59.76M2.06$8.31M$0.0438.63 Which has more risk and volatility, ORGO or PLX? Organogenesis has a beta of 1.7, indicating that its share price is 70% more volatile than the S&P 500. Comparatively, Protalix BioTherapeutics has a beta of -0.23, indicating that its share price is 123% less volatile than the S&P 500. Do institutionals & insiders have more ownership in ORGO or PLX? 49.6% of Organogenesis shares are owned by institutional investors. Comparatively, 16.5% of Protalix BioTherapeutics shares are owned by institutional investors. 33.0% of Organogenesis shares are owned by insiders. Comparatively, 6.5% of Protalix BioTherapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term. Do analysts prefer ORGO or PLX? Organogenesis presently has a consensus target price of $6.00, suggesting a potential upside of 37.93%. Protalix BioTherapeutics has a consensus target price of $15.00, suggesting a potential upside of 870.87%. Given Protalix BioTherapeutics' stronger consensus rating and higher possible upside, analysts plainly believe Protalix BioTherapeutics is more favorable than Organogenesis.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Organogenesis 0 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 2.00Protalix BioTherapeutics 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00 Does the media prefer ORGO or PLX? In the previous week, Organogenesis and Organogenesis both had 2 articles in the media. Protalix BioTherapeutics' average media sentiment score of 0.50 beat Organogenesis' score of 0.00 indicating that Protalix BioTherapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Organogenesis 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Protalix BioTherapeutics 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Is ORGO or PLX more profitable? Organogenesis has a net margin of -3.46% compared to Protalix BioTherapeutics' net margin of -21.03%. Organogenesis' return on equity of -4.00% beat Protalix BioTherapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Organogenesis-3.46% -4.00% -2.26% Protalix BioTherapeutics -21.03%-30.89%-11.74% SummaryProtalix BioTherapeutics beats Organogenesis on 8 of the 15 factors compared between the two stocks. Get Protalix BioTherapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for PLX and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding PLX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart PLX vs. The Competition Export to ExcelMetricProtalix BioTherapeuticsBiological Products IndustryMedical SectorNYSE ExchangeMarket Cap$122.99M$205.22M$5.55B$20.72BDividend YieldN/AN/A5.24%3.72%P/E Ratio-11.88N/A27.6128.07Price / Sales2.06223.65417.2338.42Price / Cash17.8022.4436.8922.53Price / Book3.295.618.034.58Net Income$8.31M-$96.61M$3.18B$985.54M7 Day Performance0.32%-0.57%2.93%2.79%1 Month Performance1.64%-1.03%3.75%5.46%1 Year Performance47.14%10.57%35.20%15.06% Protalix BioTherapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)PLXProtalix BioTherapeutics2.9137 of 5 stars$1.55+3.0%$15.00+870.9%+48.6%$122.99M$59.76M-11.88200Gap UpORGOOrganogenesis4.0859 of 5 stars$3.34+3.4%$5.50+64.7%+55.9%$423.68M$482.04M-19.65950News CoveragePRTCPureTech Health2.0384 of 5 stars$17.56+0.7%$45.00+156.3%-22.2%$421.79M$4.83M0.00100Gap UpKMDAKamada3.9326 of 5 stars$7.26+0.8%$14.67+102.0%+50.6%$417.52M$160.95M25.03360News CoverageORKAOruka Therapeutics2.193 of 5 stars$10.90-6.7%$40.38+270.4%N/A$408.10MN/A-2.42N/ANews CoverageATAIatai Life Sciences2.9812 of 5 stars$2.02-18.5%$8.67+329.0%+116.8%$404.69M$310K-2.2280Analyst ForecastOptions VolumeHigh Trading VolumeRAPPRapport Therapeutics1.3239 of 5 stars$10.88-0.4%$32.67+200.2%-48.3%$397.12MN/A-3.15N/AGap UpRGNXREGENXBIO4.5312 of 5 stars$7.86-6.8%$31.63+302.4%-19.3%$394.26M$83.33M-2.53370Positive NewsERASErasca3.0709 of 5 stars$1.39+1.5%$4.57+228.9%-36.7%$393.77MN/A-2.24120ABVXAbivax2.407 of 5 stars$6.11+2.3%$31.00+407.4%-39.0%$387.68MN/A0.0061News CoveragePositive NewsGap UpFULCFulcrum Therapeutics0.3195 of 5 stars$7.17+2.6%$6.29-12.3%+13.8%$387.03M$80M-102.41100 Related Companies and Tools Related Companies Organogenesis Alternatives PureTech Health Alternatives Kamada Alternatives Oruka Therapeutics Alternatives atai Life Sciences Alternatives Rapport Therapeutics Alternatives REGENXBIO Alternatives Erasca Alternatives Abivax Alternatives Fulcrum Therapeutics Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NYSE:PLX) was last updated on 7/5/2025 by MarketBeat.com Staff From Our PartnersBanks aren’t ready for this altcoin—are you?Our expert analysts have identified a $100 billion gap in the crypto market. Only one project is perfectly ...Crypto 101 Media | SponsoredA new rule goes live in July — and the banks are quietly cashing inA little-known regulation quietly goes into effect this July. And it's already being exploited by Wall Stre...American Alternative | SponsoredIs Elon's empire crumbling?The Tesla Shock Nobody Sees Coming While headlines scream "Tesla is doomed"... Jeff Brown has uncovered ...Brownstone Research | SponsoredPresidential Bombshell: $150T Resource to Be Released as soon as this Summer?Something extraordinary is happening in Washington. For the first time in over a century, a sitting Preside...Paradigm Press | SponsoredPost-Halving = Profit Season (Here’s How to Win It)It happens like clockwork. Every four years, the crypto market enters a new phase — and for those who know how...Crypto Swap Profits | SponsoredTrump’s New Order Could Boost Social Security Benefits by 400%If you collect—or plan to collect—Social Security, you need to see this. A new initiative tied to President...InvestorPlace | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredWhite House to reset Social Security?Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...Altimetry | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Protalix BioTherapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Protalix BioTherapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
